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 Abstract 
The fine particle fraction is a key indicator of therapeutic effectiveness of inhaled pharmaceutical 
aerosols. This paper presents a fluorescence imaging technique to visualise and characterise the 
emission of active pharmaceutical ingredient (API) fines in model formulations containing coarse 
lactose carrier and 1.5-2 µm diameter fluorescent microspheres (model API fines). A two-camera 
arrangement was used to acquire simultaneous images of spatial and temporal distribution of model 
API fines and fluidised powder formulation near the mouthpiece exit of a DPI. Digital image analysis 
showed that the model API fines were released along with the bulk of the powder dose. More rapidly 
accelerating airflows were found to cause earlier release of API fines. The fluorescence imaging 
technique analyses a substantial fraction of the aerosol plume and was found to provide effective 
time-resolved characterisation of the de-aggregation and release of API fines with consistent results 
across a wide range of model API concentrations. Future studies should demonstrate the usefulness 
of the fluorescence imaging technique across different formulations and DPI devices. 
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1.    Introduction     
Dry powder inhalers (DPI) deliver small quantities of drug in powder form for the treatment of 
respiratory diseases, such as asthma and COPD, and for systemic delivery of proteins and peptides.  
For effective drug delivery to the lungs, particles of the active pharmaceutical ingredient (API) in the 
air stream must be sufficiently small (1-5 µm) to penetrate the lower airways. However, such small 
particles are highly cohesive and must be formulated to produce particles with a size at least 40-50 
µm so that the resulting powder has good flowability and can be aerosolised effectively. This may be 
achieved by (i) processing to generate self-agglomerates of essentially pure drug, (ii) processing 
with inert excipient particles of a similar size range to generate composite agglomerates, or, (iii) 
blending with large non-active carrier particles, e.g. lactose, to which the drug particles adhere, 
(Newman & Busse, 2002; Chan & Chew, 2003; Laube et al, 2011). Powder emission from DPIs is a 
breath-actuated fluidisation and particle transport process, which is initiated by the patient sucking 
on the device mouthpiece. A sufficiently powerful inhaled air stream is needed to fluidise the powder 
and to generate the disruptive forces to overcome the inter-particulate adhesive/cohesive forces 
within the agglomerates to release inhalable-size active drug particles before the aerosol enters the 
patient’s airways (Finlay, 2001; Voss & Finlay, 2002; Coates et al, 2005; Nichols & Wynn, 2008; 
Zhou et al, 2014).  
The powder fluidisation and de-aggregation processes leading to the release of API fines in DPIs 
are at present poorly understood. Optical diagnostics are powerful techniques with considerable 
potential for the study of turbulent air flows and powder fluidisation with relevance to pharmaceutical 
inhalers. Tuley et al (2008) used high-speed imaging in conjunction with white light illumination in a 
fundamental study of fluidisation of powders with different bulk properties in a transparent, idealised 
DPI. The work revealed two distinctly different fluidisation regimes: (i) ‘erosion’ and (ii) ‘fracture’, 
which depended on the powder type. Image analysis enabled quantification of the fluidised fraction 
as a function of time for different air pressures. It was shown that lactose powders were fluidised by 
means of the ‘fracture’ regime and that the fluidised fraction depended only on instantaneous air 
pressure for these powders. Particle image velocimetry (PIV) has recently been used (Ngoc et al, 
2013) to carry out a systematic evaluation of the effect of geometry on the flow environment within 
the de-agglomeration chamber of an idealised DPI. Detailed study of the distribution of turbulence 
intensity yielded optimal de-agglomeration grid structure and dimensions as well as optimised de-
agglomeration chamber length and volume of the idealised DPI. Increases of the turbulence 
intensity were broadly found to correlate with improved aerosolisation and de-agglomeration of a 
budesonide-lactose blend. Pasquali et al (2015) used high-speed imaging and PIV to characterise 
the air flow inside a Nexthaler® DPI and outside its mouthpiece. They also observed powder 
fluidisation and aerosol transport processes inside the device. The study examined the effects of 
acceleration to steady state inhalation rates (40-80 l.min-1, rise time 0.3-1.2 s) on the temporal 
discharge of a proprietary lactose inhalation powder placebo, comprising coarse carrier particles 
blended with fine excipient particles. Imaging studies within the device allowed observation of the 
fluidisation process in situ. PIV studies showed that high swirl levels are generated in the swirl 
chamber of the device. This was observed to produce a highly turbulent swirling flow at the device 
mouthpiece, which interacted with the stationary air just outside the mouthpiece, generating 
additional turbulence. The aerosol emission process at the mouthpiece exit was observed to 
comprise two phases: (i) the main powder emission event consisting of a mixture of coarse and fine 
particles, (ii) a second emission peak containing mainly coarse carrier particles.   
One drawback of the optical set-up used in PIV studies is that the scattered light cannot discriminate 
between (a) inhalable active drug particles, (b) excipient fines which were deliberately added to the 
formulation, or, (c) fines inherent within any lactose sample. The main techniques for characterising 
aerosols emitted from inhaler devices are Cascade Impaction (CI), Laser Diffraction (LD) and Single 
Particle Aerosol Mass Spectrometry, (SPAMS): 
• Cascade impactor measurements involve quantitative analysis of drug deposition on a series 
of impactor plates, which classify an aerosol cloud sample into discrete size fractions. This 
allows determination of emitted dose, fine particle dose and particle size distribution. CI 
procedures are detailed in the pharmacopoeias (European Directorate for Quality in 
Medicines and Healthcare, 2013; US Pharmacopoeia, 2013) and are the gold standard in 
industrial quality control as well as basic research in respiratory drug delivery.  However, the 
technique consumes significant and costly analytical resource.  
• Laser diffraction is widely used to measure size distributions of DPI aerosol plumes (e.g. Sim 
et al, 2014).  This technique does not directly discriminate between API fines and excipient 
and/or carrier fines. However, Zeng et al, (2006) have established a linear correlation 
between the total aerosol fine fraction determined by a Malvern 2600 LD particle sizer and 
the FPF of the drug, (≤ 6.8µm), determined by impaction with a multi-stage liquid impinger 
(MSLI) for micronised salbutamol sulphate blends with coarse sugar carriers with added fine 
lactose.  Thus, by reference to the impactor performance of a limited number of “calibration 
formulations”, LD can be used for rapid estimation of fine drug fraction of multiple 
formulations and, hence, formulation optimisation for potential clinical study within a 
development programme.       
• SPAMS is a laser-based mass spectrometry technology with potential capability to measure 
size and chemical composition of single aerosol particles. Output data is processed to 
provide particle size distributions for individual API components within an aerosol cloud. 
Applications to both DPI, (Fergenson et al, 2013; Susz et al, 2014) and pMDI systems, 
(Morrical et al, 2015), have been described. Recently, Jetzer et al (2017) used SPAMS to 
determine the size distribution and chemical composition of particles emitted by two DPI 
combination products, namely NEXThaler® and Diskus®. The former produced significantly 
higher fine particle fraction (< 5 µm) and extrafine particle fraction (1-2 µm) suggesting more 
effective detachment of the APIs from the lactose carrier. It must be noted that the 
aerodynamic particle sizing technique used by the instrument works with a relatively small 
sample of the aerosol cloud. Moreover, the required incorporation of a settling chamber into 
the apparatus is known to lead to under-sampling of larger particles due to gravitational 
settling. This could distort the high end of the particle size distribution and, hence, creates 
errors in the mass-weighted median aerodynamic diameter. Further refinement of the 
methodology is on-going and it is claimed that chemical identification and particle size 
distribution analysis for a given component can be completed within ~ one hour. 
All three techniques have a further limitation: the aerosol is characterised ex-mouthpiece, where 
information about the complex physical processes that ultimately control the aerodynamic 
performance of the aerosol (powder fluidisation, de-agglomeration and aerosol transport) has been 
lost. To address this issue, the present work proposes the use of fluorescence imaging to study de-
aggregation and release of fines from a DPI. Fluorescent tracer dyes have been used widely in flow 
visualisation to enhance contrast and visibility (Merzkirch, 1987). Fluorescent seeding or tracer 
particles can be added to a flow, for example, to study mixing. Molecules of the seeding or tracer are 
excited from a ground state to a higher energy state by irradiation with laser light of a wavelength 
that matches with an absorption line of the molecule. Several competing pathways exist for the 
molecules to return to the ground state. The main path involves (i) relaxation to an intermediate 
energy state through radiative emission - fluorescent emission - and (ii) return back to the ground 
state by loss of further energy in the form of heat. Because the energy difference between the 
excited and intermediate states is smaller, the wavelength of the fluorescent light is longer than the 
laser irradiation. Fluorescent emission from a particle-laden flow can, therefore, be separated from 
scattered incident light by means of optical filters. Fluorescent particles have been widely used to 
study mixing processes (e.g. Towers et al. 1999).  The characteristics of fluorescence-based 
imaging that are of interest here are:  
(i) The technique is highly specific to a chemical or material, 
(ii) The results are time-resolved, so aerosol generation and development can be studied in 
considerable,  
(iii) The technique is a planar whole-field method, and hence, a substantial fraction of a 
pharmaceutical aerosol cloud is observed at every instant in time.   
 
The work reported in this paper is the second part of a two-part study of powder fluidisation in 
prototype Nexthaler® DPI. The first (Pasquali et al, 2015) focused on powder dose emission from 
the device as a function of inspiratory effort inhaled air flow rate. The present work considered the 
emission of API fines: the temporal characteristics of de-aggregation and release of a proprietary 
placebo powder. Fluorescent microspheres with diameters in the respirable range 1-5 µm were used 
as a surrogate for the API fines and blended with the Nexthaler® placebo powder. The optical 
diagnostics rig described in Pasquali et al (2015) was modified to allow simultaneous imaging of 
total scattered light (coarse carrier, excipient and API surrogate) and fluorescent light, (API 
surrogate only).  Differential detection of the fluorescent microspheres within the aerosolised cloud 
enables in situ study of powder fluidisation and release of model API fines. 
 
 
2.   Materials and Methods          
2.1  Materials 
2.1.1   Fluorescent Microspheres   
Commercially available red fluorescent polymer microspheres (Cospheric LLC, Santa Barbara, CA, 
USA) were used as the API surrogate in the present work. They are fabricated from a proprietary 
polymer with density 1.3 g.cm-3 and show peak fluorescence emission at 607 nm from excitation at 
527 nm (Cospheric Inc., 2018). According to manufacturer’s data, the microspheres have the 
following particle size distribution: d50 = 1.5-2.0 μm, d95= 3.5 μm and d99 = 5 μm, so 99% of the 
distribution is within the target range of inhalable particles.   
 
2.1.2  Fluorescent Microsphere Powder Formulations 
Chiesi’s Nexthaler® inhalation powder formulations comprise active pharmaceutical ingredients, 
(APIs), blended with a proprietary lactose-based carrier vehicle.  This carrier system is robust and 
can be manufactured at laboratory scale (≥ 50 g) or pilot/industrial scale, (≥ 1.0 kg), without 
perturbing the aerosolisation performance of an active-vehicle blend. Batches of the powder 
formulation were blended with fluorescent microspheres to nominal concentrations of 0.02%w/w, 
0.05%w/w, 0.25%w/w, 1.00%w/w and 2.00%w/w, respectively. All formulation preparation involved 
“layering” the microsphere sample between aliquots of vehicle within a customised vessel held 
within the chamber of a Turbula powder blender, (model T2F, Glen Creston, Middlesex, UK), and 
blending at 34 rpm for 90 minutes.  The presence of fluorescent microspheres on the lactose carrier 
surface was confirmed by confocal fluorescent microscopy, (Fig. 1).       
 
Figure 1: Confocal microscopy image of lactose carrier surface with 1% w/w fluorescent 
microspheres 
2.2  Methods 
2.2.1 Prototype Nexthalers 
Pre-production prototypes of the Nexthaler® DPI, (Corradi et al, 2014), were assembled from 
unfilled pieces as described by Pasquali et al (2015), and hand filled with ~1.5g of the required 
powder formulation. A different DPI prototype unit was filled for each powder with a particular 
concentration of model API fines. The aerodynamic performance of the aerosolised fluorescent 
microsphere powders (MMAD and FPF) was compared with the standard formulation containing 
BDP active using the Next Generation Impactor (NGI) at a rate of 60 l/min with a 4s suction duration.  
A fluorimeter (Jenway series 6285) was used to determine the relative mass of fluorescent 
microspheres on each impaction plate, with a 380-500nm bandpass filter used for excitation and a 
545nm high-pass cut-off filter used for emission. The gain was set to 40% for all calibration and test 
samples. Three repeat tests were carried out on the fluorescent microsphere formulations. Selected 
results from Pasquali et al (2012) are shown in Table 1. 
 
Active formulation  
BDP 1% w/w 
Fluorescent microsphere 
formulation 1% w/w 
Fine particle fraction (FFP, dp ≤ 5 µm) 58.5 ± 0.5 58.1 ± 0.5 
Mass median aerodynamic diameter 
(MMAD in µm) 
1.5 ± 0.1 1.6 ± 0.1 
 
Table 1: Comparison of FFP and MMAD of lactose/BDP formulation and formulation with fluorescent 
microsphere model API fines (test conditions: NGI at 60 l/min airflow, duration 4 s, N = 3). 
2.2.2 Optical Diagnostics Test Rig 
The experimental set-up is shown schematically in Figure 2. The pneumatic suction system is 
designed to produce systematic variations of the steady state air flow rate Qmax and the rise time 
Trise. Thermal mass flowmeter, (H), measures Qmax, the value of which is set by adjustment to the 
variable area sonic restrictor, (D). Trise can be changed by altering the capacity of the variable 
volume unit (G). Values of Qmax between 40 and 120 l.min-1 in conjunction with Trise values between 
0.3 and 1.2 s could be achieved with the present system. Instantaneous pressures were measured 
in the mouthpiece region and on the downstream side of the sonic restrictor with pressure 
transducers (Pu) and (PD), respectively. The resulting temporal profiles of pressure Pu showed an 
exponential decrease after the start of the air flow. The transient behaviour of the pressure and flow 
rate through the device will be closely correlated. As pressure Pu decreases, a corresponding 
increase of the flow rate through the DPI device takes place. This was validated by comparison of 
the resulting pressure traces with integrated velocity distributions measured with PIV at the 
mouthpiece exit. Further details of this process and the pneumatic system can be found in Pasquali 
et al (2015). 
The high speed imaging system was modified to capture the fluorescence and non-fluorescent 
scattered light signals simultaneously. The illumination source was a Nd:YLF laser with a single 
wavelength of 527 nm, which is in the green part of the visible spectrum. Suitable optics were used 
to produce a pulsed laser light sheet, (L), with a thickness of 1 mm in the vicinity of the device 
mouthpiece via an optical mouthpiece adapter (JV, JH). The incident light sheet has a frequency of 
2000 s-1 and ‘on time’ around 180 ns. It illuminates particles entrained in the air flow and also excites 
the fluorescent microspheres, which emit light in the red part of the spectrum (~607 nm).   
A cube beam splitter, (T), was used to enable simultaneous imaging of the same region with two 
Photron SA3 high-speed video cameras, (N1, N2), both synchronised to the pulsed laser light.  
Optical filters between the beam-splitter and the cameras were used to separate the red 
fluorescence signal produced by the microspheres from the green laser light scattered by all 
particles, (carrier, excipient fines and microspheres). The scattered green light is directed through 
the short-pass filter (R, cut-off ≥ 550 nm), before being recorded by camera N1. The red light emitted 
by the fluorescent particles is recorded by camera N2 via the long-pass filter (Q, cut-on ≥ 575 nm). 
The scattered green light has a much higher intensity than the fluorescent light, so a separate 
neutral density filter, (S), is placed in front of camera, N1, to produce an approximate match of the 
light intensities received by both cameras, so that the same aperture settings could be used. Two 
laser sheet alignments were used for the high-speed visualisation of the particles emerging from a 
Nexthaler® device;  
 (i) Axial plane:  along the axis of the mouthpiece to visualise the aerosol plume along its centre line 
(Figure 2, Panels a & b),  
(ii) Swirl plane: perpendicular to the axis of the mouthpiece to visualise the aerosol plume in the swirl 
plane of the device (Figure 2, Panels c & d). 
  
 
Figure 2 – Schematic of optical diagnostics test rig configurations for  
imaging in axial, (panels a & b) and swirl, (panels c & d) planes 
Key to Figure 2: 
 
A.  Vacuum pump – Edwards Speedivac ED660 
B.  Control valve – Legris Stainless steel ball valve 
C.  20 litre steel vacuum vessel  
D.  Sonic Restrictor – Made in-house 
E.  Flow Control Valve – Legris Stainless steel ball valve 
F.  Rapid Switch Solenoid Controlled Ball Valve – Omal SR15 driven with 6 bar pressure 
G. Variable Volume Unit – made in-house 
H.  Thermal Mass Flow Meter – Sierra 0-200 Sl.min-1 Accuracy: 1.0% of full scale   
I.  Particle Filter Housing with 1µm Particle Retention Filter – Pall Corporation type A/E 
JV, JH  Custom-built adaptors with optical access - PMMA construction with glass window, internal 
dimensions of 28 x 28 x 60 mm, two variations fitted with a silicone rubber seal where it meets 
the Nexthaler® Mouthpiece 
K.   Nexthaler® Device 
L. Vertical Laser Sheet  
 M.    Nikkor 105mm macro lens 
N1, N 2.  Photron APX RS High-speed cameras 
   O.     Front coated mirror 60 mm x 40 mm  
PD, Pu  Pressure Transducers – Kistler 4045A5 (25 mV/bar/mA sensitivity, natural 
frequency ≈ 80 kHz) used in conjunction with a National Instruments 6110 data logger  
Q. Long-pass optical filter with a cut-on at 575 nm  
R. Short-pass optical filter with cut-off at 550 nm 
S. Neutral density filter 
T. Cube beam splitter 
 
 
 
 
2.2.3   Effect of Airflow on Formulation Discharge from Nexthaler® 
The temporal discharge of the DPI aerosol was recorded across nine airflow suction profiles induced 
by accelerating the suction flow rates to pre-selected steady state values of 40, 60, 80 l.min-1 (Qmax), 
in conjunction with three different rise times, (Trise), 0.3, 0.7, 1.2 s, between the start of suction and 
the flow rate reaching its steady state value.  Rationale for the choice of these airflow profiles and 
the resulting differential pressure profiles recorded across the device can be found in Pasquali et al 
(2015).   
 
2.2.4 Analysis of Recorded Images 
High-speed imaging of the fluidisation of dry powder formulations yielded series of image frames. 
Figure 3 shows a sample frame illustrating a typical spatial distribution of powder aerosol in the 
mouthpiece region of the DPI. To reveal details of the plume structure, the intensity fields are shown 
on a colour scale ranging from dark blue = lowest intensity to red = highest intensity. Bright regions 
(coloured red) indicate high local concentrations of powder particles in this image of scattered light. 
The temporal release of the dry powder formulation and the model API exiting the device 
mouthpiece was characterised by means of frame-by-frame analysis using standard digital image 
analysis functions available in the numerical computing environment Matlab ® (The MathWorks, 
Inc., Natick, MA, USA). A 16 mm x 4 mm analysis region close to the device mouthpiece is 
highlighted in Figure 3. Pixel intensities I were summed in this region, yielding (ΣIn for the nth frame 
of an image series. The maximum value of the sum of the pixel intensities (MaxSum = Max((ΣI)n, n = 
1, 2,…, N)) was found for the entire series of N images representing a particular fluidisation event. 
Subsequently, the normalised sum of pixel intensities, defined as the ratio (ΣI)n/MaxSum, was 
computed for all scattered light and fluorescent images, which yielded temporal profiles of the 
emissions of powder formulation and of model API from the device as a function of time.   
 Figure 3.   Sample scattered light image of aerosol plume highlighting  
pixel analysis region for intensity measurement 
 
 
3.   Results and Discussion 
3.1  Fluorescent images – distribution of model API fines 
A typical set of fluorescent images in Figure 4 illustrates the spatial distribution of model API 
particles in the Nexthaler® aerosol during the first 25 ms after the start of the main aerosol plume 
emission. The test conditions were peak flow rate Qmax = 60 l.min-1 and rise time Trise = 1.2 s. Bright 
regions (coloured cyan) in the fluorescent image indicate high concentrations of microspheres. 
Figure 4 shows that the model API particles are concentrated near the walls of the mouthpiece exit, 
which matches the general structure of the powder aerosol described in Pasquali et al (2015). Very 
high brightness levels (coloured yellow/red), recorded during the period 0.23-0.238 s, are associated 
with a large and concentrated burst of model API fines coming out of the mouthpiece shortly after 
the actuation of the dose protector of the Nexthaler® DPI, which exposes the powder dose to the air 
stream when the suction pressure inside the device is < -2 kPa. Subsequent images show lower and 
spatially more widely distributed brightness levels in the fluorescent image. Larger, very bright spots 
also start to appear in these images, which correspond to the emission of lower amounts of de-
aggregated model API fines; possibly carrier particles, covered in attached model API fines or larger 
self-agglomerates of model API.   
3.2  Effect of air suction profile: peak flow rate and rise time on model API fines emission 
The recorded image series for all suction conditions were analysed in order to show the temporal 
release of the model API fines by summing the pixel intensities in the analysis region defined in 
Figure 3 for each frame recorded; the results are shown in Figure 5. The maximum fluorescent 
signal intensity was insensitive to the flow rate, but the timing of the peak intensity was found to vary 
with peak flow rate of the suction profile. The main fluorescent emission peak also appeared more 
quickly when the rise time was shorter. These trends are largely due to the dependence on suction 
profile of the timing of the -2 kPa trigger point for movement of the dose protector (Figure 4b in 
Pasquali et al 2015). As a consequence, fluidisation of the powder dose will commence sooner after 
the start of the air flow when Qmax is higher and/or Trise is shorter. The start of the main emission 
peak was more erratic for 40 l.min-1 peak flows, because the steady-state pressure difference across 
the device is 2 kPa at this flow rate. This is close to the trigger point for dose protector movement, 
so exposure of the powder dose to the air flow occurs haphazardly at this experimental condition.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Fluorescent intensity mages in mouthpiece exit region of Nexthaler® during 25 ms after 
the start of powder emission (conditions: 1% w/w model API fines, Qmax = 60 L/min, Trise = 1.2 s) 
a) 0.124 s b) 0.126 s c) 0.128 s 
d) 0.130 s e) 0.132 s f) 0.134 s 
g) 0.136 s h) 0.138 s i) 0.140 s 
j) 0.142 s k) 0.144 s l) 0.146 s 
0 1 0.5 
Light intensity, normalised to maximum  
0.25 0.75 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Fluorescent signal intensity count in analysis region as function of time for powder 
formulation with 1% w/w model API fines; air suction profiles with different suction rise time Trise and 
peak flow rates (a) Qmax = 40 l.min-1, (b) Qmax = 60 l.min-1, (c) Qmax = 80 l.min-1 
 
3.3  Scattered and fluorescent light images – emission of all powder vs. model API fines  
The degree of correlation between the emission of model API fines and the whole powder aerosol 
can be investigated by comparing pairs of simultaneous scattered light and fluorescent light images 
acquired by the two-camera optical setup.  An example of such an image pair is given in Figure 6.  
When examining image pairs, differences in the relative brightness patterns between fluorescent 
and scattered images should be interpreted with some care, since, even after the addition of a 
neutral density filter along the scattered light path to the camera, the dynamic range of the 
a) 40 l.min
-1 
b) 60 l.min
-1 
c) 80 l.min
-1 
brightness levels of the fluorescent and scattered light images is not necessarily identical in the two 
images due to differences in the temporal release profiles of coarser powder fractions and model 
API fines.   
 
Figure 6 – Sample images from the simultaneous twin camera recording of aerosol plume just 
outside the mouthpiece exit; (I) = region with low model API fines content; (II) = carrier particle with 
attached model API fines; (III) = carrier particle without model API fines 
 
Figure 6 shows that the spatial distributions of brightness of the scattered and fluorescent light 
images of the aerosol plume are broadly similar. This suggests that the model API fines are well 
distributed throughout the powder, which is as expected, because high levels of turbulent mixing in 
the swirl chamber and device mouthpiece will mix fines thoroughly. There are, however, some bright 
regions in the scattered image, which do not appear to have a corresponding bright region in the 
fluorescent image (I) indicating a relatively low local concentration of model API fine. Concentrated 
bright spots in both fluorescent and scattered images (II) show the presence of large particles with 
significant fluorescent microspheres (model API) fines content, which could indicate lactose carrier 
particles with model API fines still attached to the surface or agglomerates of lactose and/or 
excipient fines with significant model API fines content. Large particles that appear fainter in the 
fluorescent image than in the scattered light image (III) represent carrier particles without attached 
microspheres or agglomerates of lactose/excipient fines without model API fines.   
Figure 7 gives a sequence of image pairs acquired during an experiment with the following suction 
conditions: peak flow rate 60 l.min-1 and rise time 1.2 s.  High brightness levels in concentrated 
regions were recorded in both image sets during a 10 ms time interval between 0.135 s and 0.145 s 
showing that release of most of the model API fines coincides with the main burst of powder 
emission, shortly after the actuation of the dose protector. After the rapid entrainment of the powder 
dose into the airflow, the powder is transported from the swirl chamber through a cylindrical outlet 
tube. The axial plane visualisation in Figure 7 and corresponding swirl-plane visualisation in Figure 8 
both show that powder is most concentrated near the walls of the cylindrical tube due to the 
centrifugal forces acting on the particles, which travelled along spiralling paths as they emerge from 
the mouthpiece of the device (Pasquali et al, 2015).   
After the main peak of powder emission, the fluorescent images show lower and more distributed 
brightness levels suggesting the emission of much lower amounts of de-aggregated model API fines 
during this phase of the powder fluidisation event. Small brighter spots in these images are 
associated with larger carrier particles and/or agglomerates of fines. These larger particles will 
experience a pronounced outward displacement and arrive at the mouthpiece later than the fines 
due to their higher inertia (see Figures 9 and 10).  
The general similarity of the brightness patterns in the scattered and fluorescent images consistently 
appears in all other image sets acquired under different suction conditions. This confirms that model 
API fines are thoroughly mixed with the aerosol plume and that the emission of de-aggregated 
model API is largely correlated with emission of other fines (excipient and carrier).   
 Figure 7: Axial plane visualisation of scattered and fluorescent intensity image pairs in 
mouthpiece exit region of Nexthaler® over a period of 15 ms representing the main fines 
emission (test conditions: Qmax = 60 l.min−1, Trise = 1.2 s) 
 Figure 8: Swirl plane visualisation of scattered and fluorescent intensity image pairs in 
mouthpiece exit region of Nexthaler® over a period of 15 ms representing the main fines 
emission (test conditions: Qmax = 60 l.min−1, Trise = 1.2 s).  
3.4  Effect of air suction profile: model API fines vs. whole powder aerosol emission 
The recorded fluorescent and scattered intensity image sets were analysed in order to compare the 
temporal release of the model API fines with the whole powder aerosol, respectively.  The pixel 
intensities were summed in the analysis region defined in Figure 5 and normalised by the peak 
intensity as explained in section 2.2.4. Figure 9 compares the normalised fluorescent signal intensity 
(model-API only) with the normalised scattered signal intensity (all powder) for a series of 
experiments with a powder formulation containing 1% w/w concentration of model API in conjunction 
with a peak air flow rate of 60 l.min-1 and rise times 0.3, 0.7 and 1.2 s.  The main features of the 
emission profiles were as follows: 
A. Initial (premature) emission of particles early on in the suction profile as the airflow starts and 
before the ‘breath activated mechanism’ is triggered.    
B. Main peak, just after the dose protector is withdrawn, releasing the formulation to the airflow. 
C. Emission tail, reduced quantities of fine particles continue to leave the device and when most 
of the carrier particles leave the device. 
D. Small intensity peaks after the main emission as occasional carrier particles and/or 
lactose/excipient agglomerates still leave the device. 
In all of the traces, the shape of the main peak is nearly identical for the fluorescent and scattered 
intensity images. However, the emission tail is higher for the scattered light trace than the 
fluorescent light trace. The results of these experiments imply that the release of de-aggregated 
model API fines is concentrated toward the start of the powder fluidisation event and its release 
profile is identical to that of carrier particles and lactose/excipient fines, which represent the large 
majority of powder particles. Carrier particles and/or agglomerates of lactose/excipient fines are 
responsible for the larger emission peak in the scattered light signal during the emission tail. Most of 
the model API fines have been released earlier, so the emission tail in the fluorescent signal is 
considerably reduced. Result trends for experiments with 40 and 80 l.min-1 (not shown here for 
brevity) were found to be very similar.    
  
                                                                                                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Comparison of fluorescent signal intensity and scattered signal intensity in analysis region for 
suction profiles with Qmax = 60 l.min-1 (a) Trise = 0.3 s, (b) Trise = 0.7 s, (c) Trise = 1.2 s 
The overall duration of the aerosol plume emission was found by determining the time from the start 
of the main intensity peak to the moment when 90% of the aerosol plume was emitted by numerical 
integration of the intensity-time profiles. The results of these calculations for all flow conditions are 
given in Table 2. The release of the fluorescent particles (model API) is completed earlier than the 
whole powder dose. The difference between the release times of model API and the whole powder 
was found to be greater for higher peak flow rates and shorter rise times. More flow energy is 
available for de-aggregation of fines from carrier particles when the flow changes are more abrupt, 
causing the model API to separate from the carrier particles earlier in the release process.   
a) Trise = 0.3 s 
b) Trise = 0.7 s 
c) Trise = 1.2 s 
A 
B 
C 
D 
  
Steady 
state air 
flow rate 
(l.min-1) 
Rise time of 
ramp profile 
(s) 
Time TAPI to release 
90% of fluorescent 
(model API) content 
(ms) 
Time Tall to release 
90% of whole 
formulation  
(ms) 
Difference Tall - TAPI 
(ms) 
40 0.3 136.5 151.0 14.5 
40 0.7 132.0 143.5 11.5 
40 1.2 126.5 129.5 3.0 
60 0.3 58.5 78.0 19.5 
60 0.7 87.5 101.5 14.0 
60 1.2 94.0 102.5 8.5 
80 0.3 40.5 62.0 21.5 
80 0.7 56.5 71.0 14.5 
80 1.2 74.0 82.5 8.5 
 
Table 2: Time to release of 90% of model API content and 90% of whole powder dose  
(powder formulation: 1% w/w model API fines) 
 
3.5  Effect of concentration of fluorescent particles 
A series of experiments was carried out to study the effect of variations of the model API content 
spanning the range of practical API concentrations found in typical DPI formulations. The main 
purpose was to understand whether the temporal profile of API release was affected by fluorescent 
particle concentration. Chiesi’s proprietary Nexthaler® carrier and excipient were blended with 
fluorescent microspheres to produce the following nominal model-API w/w concentrations: 0.02%, 
0.05%, 0.25%, 1% and 2%. After loading into Nexthaler® prototype DPIs, these formulations were 
tested with air suction conditions corresponding to peak flow rates of 40, 60 and 80 l.min-1 in 
conjunction with the intermediate rise time of 0.7 s. Separate inhaler devices were used for the 
testing of each formulation, resulting in small variations in the triggering of the dose release.  
The temporal development of each of the aerosol plumes generated during these tests was very 
similar to those described in the previous section. Figure 10 shows typical fluorescent signal 
intensity traces in the analysis region as a function of time for the experiments conducted with a 
peak flow rate of 80 l.min-1. The maximum signal intensity was found to be insensitive to the peak 
flow rate, but the timing of the maximum intensity again varied somewhat with air flow rate and rise 
time, which was in general agreement with the results for powder emission of placebo formulation 
(without active or model API) described in Pasquali et al (2015).   
The peak fluorescent intensity increases with fluorescent particle concentration as expected 
(maximum of ~104 counts for 0.02% w/w concentration in Fig. 10.a up to 1.6×106 for the 2% w/w 
concentration in Fig. 10.e). The results of quantitative analysis of the fluorescent signal intensity 
obtained from analysis of the rectangular 16 mm x 4 mm analysis region just outside the mouthpiece 
exit are given in Table 3.  
 
Nominal concentration of 
fluorescent particles (w/w) 
Total fluorescent intensity count recorded on camera sensor 
within the analysis region 
0.02 151 129 104 
0.05 302 201 193 
0.25 2000 1590 1684 
1.00 12290 10521 13779 
2.00 27356 40419 28842 
Flow rate  (l.min-1) 40 60 80 
 
Table 3: Total fluorescent intensity count for different peak flow rates and fluorescent microsphere 
concentrations after aerosolisation of lactose blend 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.a-e – Fluorescent light intensity traces for model-API concentrations between 0.02% w/w 
and 2% w/w at peak flow rate of 80 l.min-1 and rise time of 0.7 s. 
The area under the fluorescent intensity traces represents the total pixel intensity count for each test 
condition. Table 3 shows that, for a fixed fluorescent particle concentration, the total intensity count 
was found to vary somewhat with peak flow rate. Furthermore, the data in Table 3 highlight that the 
total intensity count increases as the concentration of fluorescent microspheres goes up. The total 
intensity is not exactly proportional to concentration and independent of flow rate due to variations 
that occur between experiments, most notably, variation in laser power affects the light intensities 
received by the cameras during different experiments. This effect can be reduced by considering the 
ratio of the total fluorescent intensity count and the total scattered intensity count during the same 
fluidisation experiment. This normalisation is useful, because variations of the laser light intensity 
between different tests affect the pixel intensities for whole powder dose and the fines in the same 
way.   
 
 
Figure 11: Fluorescent signal intensity normalised by scattered light intensity vs. % w/w 
concentration of fluorescent microspheres  
 
Figure 11 shows that the relationship between the normalised fluorescent light intensity and the % 
w/w concentration of fluorescent microspheres is almost linear. If the fluorescent signal intensity was 
dependent purely on the number of fluorescent particles in the formulation, the expected relationship 
would be a straight-line intersecting the origin. For dispersed aerosols with sufficiently large inter-
particle distance, the contribution due to de-aggregated fines should be proportional to the number 
concentration of model API fines, hence, linearly proportional to the % w/w of model-API. The most 
likely cause of departures from linear behaviour is loss of visible particles.  This may be caused by:  
• Fines deposition inside the device passages. 
• Incomplete de-aggregation causing a fraction of the microspheres to remain attached to 
carrier particles.  
Even a small number of fluorescent microspheres lost in this way could cause a substantial drop in 
recorded fluorescence signal at lower concentrations. An indication that fines attached to larger 
carrier particles may be responsible for this effect, is found in the large and rapid intensity 
fluctuations towards the end of the main peak in the intensity-time traces corresponding to lower 
model-API concentrations (see Figs 10.a-b).  Traces corresponding to high model-API concentration 
results are much more smooth (see Fig 10.e). De-aggregated fines are rapidly dispersed throughout 
the aerosol and will generate smoothly varying fluorescent intensity-time traces. Pasquali et al 
(2015) suggested that spikes in the later part of the scattered light intensity-time traces are 
associated with the emission of individual carrier particles. At the lowest concentration of model API 
fines, a larger proportion of model API fine particles remains attached to such large particles, which 
would explain the large fluorescent intensity spikes.   
The observed trends are in agreement with the theory of blend structure and influence of drug 
loading on fine-particle dose in carrier formulations proposed by Young et al (2011). During 
blending, the sites on carrier particles with the strongest adhesion (i.e. highest adhesion energy) are 
populated first by fines. As the concentration of drug fines increases, sites with lower adhesion 
energy will be populated next. At very high fines concentrations, all sites will be filled with drug fines 
and additional fines will adhere to already-attached drug fines, forming a second attached layer.  
After fluidisation, the aerosol plume will mainly contain the most loosely-bound fines originating from 
sites with low adhesion energy. The fine particles on the sites with high adhesion energy are more 
likely to remain attached. Assuming that the number of such high adhesion sites is uniformly 
distributed amongst carrier particles, this loss of strongly-adhered fines will cause a 
disproportionately large effect on the fluorescent intensity traces when the concentration of 
fluorescent microspheres is low.  Since only one side of each carrier particle is visible to the camera, 
a substantial fraction of the attached fines remains invisible to the camera.  This could explain the 
disproportionate reduction of the normalised fluorescent signal intensity to reduce at low 
concentrations and, hence, the non-linear relationship between fluorescent intensity and model API 
concentration.      
 4. Concluding Remarks 
The fluorescent imaging system described in this paper has been shown to provide an effective 
method for characterising the release of model API fines from a dry powder inhaler under different 
flow rate profiles and different model API concentrations. The Nexthaler® DPI is designed to deliver 
consistent powder aerosols with extrafine (1-2 µm) particle content with minimal effect of inhaled air 
flow rate. A key design feature is its dose protector, which prevents powder emission until the 
suction pressure of the inhaled air exceeds -2 kPa. This ensures that the air flow has accelerated 
sufficiently and reduces the dependence of delivered drug dose on a patient’s inspiratory effort. 
Buttini et al (2015) and Buttini et al (2016) considered this issue and produced a significant dataset 
to confirm that the performance of the Nexthaler® device was insensitive to applied air flow rate.  
The fluorescent imaging system has provided further confirmation of these findings, showing that the 
API fines are emitted efficiently for a range of different suction conditions and model API 
concentrations that are representative of practical formulations.  
Furthermore, the fluorescent imaging technique has given detailed information relating to the 
temporal profile and the spatial distribution of model API fines during their emission. The release of 
a large fraction of the model API occurred in a short 10-20 ms burst after the start of the particle 
emission event; the remainder was released more gradually over a 100-200 ms period.  The pattern 
of release of the model API was substantially independent of suction conditions, but, for suction 
profiles with more rapid flow acceleration (shorter rise time and higher peak flow) the -2 kPa suction 
pressure needed to trigger movement of the dose protector of the Nexthaler® DPI is reached earlier. 
Thus, the powder dose is fluidised more quickly after the start of suction, leading to faster release of 
the API fines.    
The fluorescent imaging technique gave consistent results across a wide range of model API 
content without the need to change filters, lens settings, or laser power. The two-camera 
arrangement enables direct comparison of the release of the model API and the whole formulation. 
Test results have shown that, while most of the model-API particles ares released from the carrier 
particles during the entrainment process, in all cases some of large particles with significant 
fluorescent microsphere content were observed. The total fluorescence intensity, normalised by the 
total scattered light intensity, increases with fluorescent particle concentration in an almost linear 
fashion. Reduced intensity occurs for low concentration formulations. The reduced visibility of the 
model API fines at low concentrations follows trends that are also predicted by a model of the effect 
of drug loading on FPF proposed by Young et al (2011).   
The work reported in the present manuscript demonstrates the merits of fluorescent imaging using 
prototypes of the Nexthaler® DPI and proprietary development placebo formulation. However, the 
optical diagnostics and digital image analysis techniques are completely generic and can be used 
for detailed fundamental study of powder fluidisation inside a DPI device by making use of 
transparent model devices. Moreover, the methods can also be applied during development of DPI 
products as soon as realistic prototype devices are available. Future studies should realise the 
potential of this optical diagnostic technique by further in-depth image analysis to reveal details of 
the processes leading to drug fines emission in model formulations containing coarse lactose carrier 
and fluorescent microspheres. 
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